Search
Hengrui Medicine's Subsidiary, Realstone Biosciences, Secures Approval for RSS0393 Ointment Clinical Trials
3 day ago /
Read about 0 minute
Author：小编
Realstone Biosciences, a subsidiary of Hengrui Medicine, has been granted the "Notice of Approval for Drug Clinical Trial" by the National Medical Products Administration for its RSS0393 Ointment. This milestone paves the way for the commencement of clinical trials in the near future. RSS0393 Ointment, an innovative formulation independently developed by Hengrui Medicine, incorporates a PDE4 small molecule inhibitor. By inhibiting PDE4 activity, this ointment aims to alleviate tissue damage and inflammation, making it a promising treatment option for atopic dermatitis. Market projections indicate that global sales of comparable products in this category will reach approximately US$254 million by 2024.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
